MCID: VRL010
MIFTS: 52

Viral Hepatitis

Categories: Cancer diseases, Gastrointestinal diseases, Genetic diseases, Immune diseases, Infectious diseases, Liver diseases, Mental diseases, Nephrological diseases, Rare diseases

Aliases & Classifications for Viral Hepatitis

MalaCards integrated aliases for Viral Hepatitis:

Name: Viral Hepatitis 12 54 3 15 70 32
Hepatitis, Viral, Animal 44 70
Animal Viral Hepatitis 12 17
Viral Hepatitis with Hepatic Coma 12
Human Viral Hepatitis 12

Classifications:



External Ids:

Disease Ontology 12 DOID:1884
MeSH 44 D006524
UMLS 70 C0019194 C0042721

Summaries for Viral Hepatitis

CDC : 3 Hepatitis means inflammation of the liver. The liver is a vital organ that processes nutrients, filters the blood, and fights infections. When the liver is inflamed or damaged, its function can be affected. Heavy alcohol use, toxins, some medications, and certain medical conditions can cause hepatitis. However, hepatitis is often caused by a virus. In the United States, the most common types of viral hepatitis are hepatitis A, hepatitis B, and hepatitis C.

MalaCards based summary : Viral Hepatitis, also known as hepatitis, viral, animal, is related to hepatitis a and acute liver failure. An important gene associated with Viral Hepatitis is GPT (Glutamic--Pyruvic Transaminase), and among its related pathways/superpathways are PI3K-Akt signaling pathway and Allograft rejection. The drugs Peginterferon alfa-2b and Ribavirin have been mentioned in the context of this disorder. Affiliated tissues include liver, kidney and bone, and related phenotypes are Reduced mammosphere formation and liver/biliary system

Disease Ontology : 12 A hepatitis that involves viral infection causing inflammation of the liver.

Wikipedia : 73 Viral hepatitis is liver inflammation due to a viral infection. It may present in acute form as a recent... more...

Related Diseases for Viral Hepatitis

Diseases in the Hepatitis family:

Hepatitis C Virus Hepatitis a
Hepatitis C Viral Hepatitis
Hepatitis B Hepatitis D
Autoimmune Hepatitis Hepatitis E
Autoimmune Hepatitis Type 2 Autoimmune Hepatitis Type 1

Diseases related to Viral Hepatitis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 714)
# Related Disease Score Top Affiliating Genes
1 hepatitis a 32.8 TNF SERPINA1 SEPSECS IFNA1 GPT F2
2 acute liver failure 32.7 SLC17A5 GPT F2
3 hepatitis d 32.6 IFNA2 IFNA1 GPT F2
4 non-a-e hepatitis 32.6 F2 ALB
5 hepatitis e 32.5 TNF MIR122 GPT F2 ALB
6 hepatitis b 32.1 TNF SLC17A5 MX1 IFNA2 IFNA1 GPT
7 hepatitis 32.0 TNF SLC17A5 SEPSECS KRT18 IL18BP IFNA2
8 hepatitis c 31.9 TNF MX1 MIR122 KRT18 IFNA2 IFNA1
9 hepatic coma 31.8 GPT F2 ALB AFP
10 splenomegaly 31.4 IFNA2 IFNA1 FAS
11 cholestasis 31.4 SLC17A5 SERPINA1 GPT GGT1 F2 ALB
12 hepatic encephalopathy 31.4 TNF SLC17A5 GPT F2 ALB
13 disease by infectious agent 31.3 TNF SERPINA1 MIR122 IFNA1 GPT ALB
14 cryoglobulinemia 31.3 TNF IFNA2 IFNA1 GPT
15 hemosiderosis 31.3 HFE GPT ALB
16 obstructive jaundice 31.3 TNF SLC17A5 GPT GGT1 F2 ALB
17 acute kidney failure 31.3 GPT F2 ALB
18 portal hypertension 31.2 TNF GPT F2 ALB
19 guillain-barre syndrome 31.2 TNF FAS ALB
20 aplastic anemia 31.2 TNF IFNA1 HFE FASLG FAS ALB
21 proteasome-associated autoinflammatory syndrome 1 31.1 TNF IFNA1 ALB
22 schistosomiasis 31.1 TNF GPT F2 ALB
23 cryoglobulinemia, familial mixed 31.1 IFNA2 IFNA1
24 syphilis 31.1 TNF GPT FAS F2 ALB
25 hemolytic anemia 31.1 TNF IFNA2 IFNA1 HFE FASLG FAS
26 thyroiditis 31.1 TNF IFNA1 FASLG
27 typhoid fever 31.1 TNF GPT F2 ALB
28 cholecystitis 31.1 KRT18 GPT F2 ALB
29 alcohol use disorder 31.1 SLC17A5 HFE GPT GGT1 ALB ABCB7
30 hepatorenal syndrome 31.1 GPT F2 ALB
31 exanthem 31.1 TNF IFNA1 GPT F2 ALB
32 opisthorchiasis 31.0 TNF GPT GGT1 AFP
33 disseminated intravascular coagulation 31.0 TNF GPT F2
34 immune deficiency disease 31.0 TNF IFNA1 GPT FASLG FAS
35 liver cirrhosis 31.0 TNF SLC17A5 SERPINA1 MIR122 KRT18 IFNA2
36 portal vein thrombosis 31.0 IFNA1 F2 AFP
37 bilirubin metabolic disorder 31.0 TNF SLC17A5 SERPINA1 GPT GGT1 F2
38 varicose veins 31.0 TNF HFE F2
39 fatty liver disease 30.9 TNF SLC17A5 MIR122 KRT18 HFE GPT
40 acalculous cholecystitis 30.9 GPT F2 ALB
41 primary biliary cholangitis 30.9 SLC17A5 SEPSECS MIR122 GPT GGT1 F2
42 dysentery 30.9 TNF IFNA2 GPT ALB
43 hypothyroidism 30.9 TNF IFNA2 IFNA1 GPT ALB
44 non-alcoholic fatty liver disease 30.8 TNF SERPINA1 MIR122 KRT18 HFE GPT
45 siderosis 30.8 SERPINA1 HFE GPT
46 acquired immunodeficiency syndrome 30.8 TNF IFNA2 IFNA1 ALB
47 thrombocytopenia 30.8 TNF IFNA2 IFNA1 GPT FASLG FAS
48 cholangitis 30.8 TNF GPT GGT1 F2 ALB
49 hypersplenism 30.8 GPT F2 ALB
50 deficiency anemia 30.8 TNF IFNA2 IFNA1 HFE GPT F2

Graphical network of the top 20 diseases related to Viral Hepatitis:



Diseases related to Viral Hepatitis

Symptoms & Phenotypes for Viral Hepatitis

GenomeRNAi Phenotypes related to Viral Hepatitis according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Reduced mammosphere formation GR00396-S 9.23 AFP ALB FAS FASLG FGL2 GGT1

MGI Mouse Phenotypes related to Viral Hepatitis:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 liver/biliary system MP:0005370 9.61 ABCB7 AFP ALB FAS FASLG HFE
2 mortality/aging MP:0010768 9.47 ABCB7 AFP ALB F2 FAS FASLG

Drugs & Therapeutics for Viral Hepatitis

Drugs for Viral Hepatitis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 103)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Peginterferon alfa-2b Approved Phase 4 99210-65-8, 215647-85-1
2
Ribavirin Approved Phase 4 36791-04-5 37542
3
Maraviroc Approved, Investigational Phase 4 376348-65-1 3002977
4
Peginterferon alfa-2a Approved, Investigational Phase 4 198153-51-4 5360545
5
Entecavir Approved, Investigational Phase 4 142217-69-4 153941
6
Sofosbuvir Approved Phase 4 1190307-88-0 45375808
7
Velpatasvir Approved, Investigational Phase 4 1377049-84-7 67683363
8
Tenofovir Experimental, Investigational Phase 4 147127-20-6 464205
9
Adefovir Investigational Phase 4 106941-25-7
10 Interferon-alpha Phase 4
11 Interferon alpha-2 Phase 4
12 interferons Phase 4
13 Anti-Retroviral Agents Phase 4
14 Anti-HIV Agents Phase 4
15 Reverse Transcriptase Inhibitors Phase 4
16 Antimetabolites Phase 4
17 Antiviral Agents Phase 4
18 Sofosbuvir-velpatasvir drug combination Phase 4
19 Analgesics, Opioid Phase 4
20 Liver Extracts Phase 4
21 Antibodies Phase 4
22 Immunoglobulins Phase 4
23 Hepatitis C Antibodies Phase 4
24
Telbivudine Approved, Investigational Phase 3 3424-98-4 159269
25
Angiotensin II Approved, Investigational Phase 3 68521-88-0, 11128-99-7, 4474-91-3 172198
26
Irbesartan Approved, Investigational Phase 3 138402-11-6 3749
27
Nicotinamide Approved, Investigational Phase 2, Phase 3 98-92-0 936
28
Milk thistle Approved, Experimental, Investigational Phase 2, Phase 3 65666-07-1
29
Folic acid Approved, Nutraceutical, Vet_approved Phase 2, Phase 3 59-30-3 6037
30
Riboflavin Approved, Investigational, Nutraceutical, Vet_approved Phase 2, Phase 3 83-88-5 493570
31
Niacin Approved, Investigational, Nutraceutical Phase 2, Phase 3 59-67-6 938
32
Thiamine Approved, Investigational, Nutraceutical, Vet_approved Phase 2, Phase 3 70-16-6, 59-43-8 1130
33 Giapreza Phase 3
34 Angiotensin Receptor Antagonists Phase 3
35 Angiotensinogen Phase 3
36 Antihypertensive Agents Phase 3
37 Angiotensin II Type 1 Receptor Blockers Phase 3
38 Vitamins Phase 2, Phase 3
39 Vitamin B9 Phase 2, Phase 3
40 Protective Agents Phase 2, Phase 3
41 Antioxidants Phase 2, Phase 3
42 Folate Phase 2, Phase 3
43 Vitamin B Complex Phase 2, Phase 3
44 Vitamin B2 Phase 2, Phase 3
45 silymarin Phase 2, Phase 3
46 Nicotinic Acids Phase 2, Phase 3
47 Thiamin Phase 2, Phase 3
48 Vitamin B3 Phase 2, Phase 3
49
Ledipasvir Approved Phase 2 1256388-51-8 67505836
50
Sorafenib Approved, Investigational Phase 1, Phase 2 284461-73-0 216239 406563

Interventional clinical trials:

(show top 50) (show all 63)
# Name Status NCT ID Phase Drugs
1 Phase IV Study of Effectiveness of Interferon and Ribavirin Treatment in Thalassemia Major Patients With Chronic Viral Hepatitis C Unknown status NCT00887081 Phase 4 PEG-IFN alpha2a or PEG-IFN alpha2b and Ribavirin
2 A Multicenter, Randomized, Blinded, Placebo-controlled Study To Evaluate The Safety Of Maraviroc In Combination With Other Antiretroviral Agents In Hiv-1-infected Subjects Co-infected With Hepatitis C And/or Hepatitis B Virus Completed NCT01327547 Phase 4 Maraviroc;Placebo
3 A Multicenter Randomized Controlled Open-label Trial of Tenofovir vs. Tenofovir Plus Entecavir in Chronic Hepatitis B Patients With Genotypic Resistance to Entecavir and Partial Virologic Response to Ongoing Treatment Completed NCT01639092 Phase 4 Tenofovir;Tenofovir;Entecavir
4 A Multicenter Randomized Controlled Open-label Trial of Tenofovir Plus Entecavir Combination vs. Tenofovir Monotherapy in Chronic Hepatitis B Patients With Genotypic Resistance to Adefovir and Partial Virologic Response to Ongoing Treatment Completed NCT01639066 Phase 4 Tenofovir;Entecavir;Tenofovir
5 Non-randomized Prospective Study on the Effect of Antiviral Therapy With Peginterferon Alfa-2a and Ribavirin on Bone Mineral Density and Metabolism in Patients With Chronic Viral Hepatitis C Genotype 1 Completed NCT00948220 Phase 4 peginterferon alfa-2a and ribavirin
6 Hepatitis B Virus Vaccination in HIV-positive Patients and Individuals at High Risk for HIV Infection: an Open-label Randomized Clinical Trial Recruiting NCT03854630 Phase 4 Engerix-B
7 Increasing Access to Hepatitis C Treatment in Opioid Endemic Rural Areas: The Kentucky Viral Hepatitis Treatment (KeY Treat) Study Recruiting NCT03949764 Phase 4 Sofosbuvir/velpatasvir (Epclusa®)
8 Screening for Hepatitis C and Hepatitis B in Inpatients: A Toronto Viral Hepatitis Care Network (VIRCAN) Collaboration Not yet recruiting NCT04620226 Phase 4
9 Hepatitis C Virus Post-Exposure Prophylaxis for Health Care Workers Withdrawn NCT01766115 Phase 4 Telaprevir
10 A Randomized, Open-label Trial Comparing Telbivudine vs, Entecavir in Reducing Serum HBsAg Levels in Patients With HBeAg-positive Chronic Hepatitis B Who Have Achieved Serum HBV DNA Undetectability by Preceding Entecavir Treatment Completed NCT01595685 Phase 3 Telbivudine;Entecavir
11 Study of the Effects of a Sartan on Hepatic Fibrosis Progression in Chronic Viral Hepatitis C Completed NCT00265642 Phase 3 Irbesartan;placebo
12 A Multicentre, Double-blind, Randomized, Placebo-controlled, Phase II/III Study to Evaluate the Safety and Efficacy of 280 mg and 420 mg Silymarin TID (Legalon® Capsules) Administered for Four Weeks in Subjects With Acute Viral Hepatitis With a Four Week Follow-up Period Terminated NCT00755950 Phase 2, Phase 3
13 A Multicenter, Open-label, Randomised, Comparative, Parallel-Arm, Phase II Study to Assess Efficacy and Safety of Myrcludex B in Combination With Peginterferon Alfa-2a Versus Peginterferon Alfa-2a Alone in Patients With Chronic Viral Hepatitis B With Delta-agent Completed NCT02888106 Phase 2 Myrcludex B;PEG IFN alfa-2a;Tenofovir
14 Pilot Study to Assess Efficacy and Safety of Sofosbuvir/Ledipasvir (GS-5885) Fixed-dose Combination in NS3/4A Protease Inhibitor-experienced Subjects With HCV Genotype 1 Infection and HIV Co-infection Completed NCT02125500 Phase 2 Sofosbuvir/Ledipasvir fixed dose
15 Multicenter Open and Prospective Trial Assessing the Efficacy of Vitamin D Supplementation in Addition to Pegylated Interferon Plus Ribavirin in Null-Responders Patients With Chronic Viral Hepatitis C Genotype 1 or 4 Completed NCT01226446 Phase 2 vitamin D
16 A Phase 2 Trial of NOV-205 in Chronic Viral Hepatitis C Patients (Genotype 1) Who Have Failed Treatment With Pegylated Interferon Plus Ribavirin Completed NCT01058512 Phase 2 NOV-205
17 An Open Study to Investigate the Effects of Chronic Viral Hepatitis B or C on the Pharmacokinetics of Cholyl-lysyl-fluorescein (NRL972) Before, During and After Standard Treatment. Completed NCT00915057 Phase 2 NRL972
18 A Phase 1/2, Dose-escalation, Open-label, Non-comparative Study of Nivolumab or Nivolumab in Combination With Ipilimumab in Advanced Hepatocellular Carcinoma Subjects With or Without Chronic Viral Hepatitis; and a Randomized, Open-label Study of Nivolumab vs Sorafenib in Advanced Hepatocellular Carcinoma Subjects Who Are Naive to Systemic Therapy Active, not recruiting NCT01658878 Phase 1, Phase 2 Sorafenib;Ipilimumab;Cabozantinib
19 A Randomized, Open-Label Phase II Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of Hepatitis C Immune Globulin Intravenous (Human), Civacir(TM), in Liver Transplant Recipients Terminated NCT00473824 Phase 2
20 An Open Label, Dose Escalation Study of EMZ702 in Combination With Pegylated Interferon and Ribavirin in Patients With Chronic Hepatitis C Genotype 1 Non-responsive to Prior Therapy With Pegylated Interferon and Ribavirin Completed NCT00230854 Phase 1 EMZ702
21 Comparative Pharmacokinetics and Pharmacodynamics, and Safety of Two Products Containing Recombinant Human Interferon Alpha-2 Conjugated to Polyethylene Glycol in Healthy Volunteers - Phase 1. Completed NCT01889849 Phase 1 BIP 48;Pegasys
22 A Randomized, Placebo Controlled, Phase 1b Trial to Evaluate the Safety and Pharmacokinetics of NOV-205 in Chronic Viral Hepatitis C Subjects (Genotype 1) Who Have Failed Treatment With Pegylated Interferon Plus Ribavirin Completed NCT00372983 Phase 1 NOV-205
23 Differential Gene Expression in Liver Tissue and Blood From Individuals With Chronic Viral Hepatitis With or Without a Complicating Hepatoma or Autoimmune Liver Disease Unknown status NCT00160940
24 Long-term Follow Up of Viral Hepatitis in Uremic Patients in Taiwan Unknown status NCT01766895
25 HIV Indicator Diseases Survey Across Europe Unknown status NCT01196468
26 A Prospective Evaluation of the Role of Transient Elastography (Fibroscan) in Differentiating Patients of Acute Severe Viral Hepatitis and Acute on Chronic Liver Failure Unknown status NCT01866072
27 Natural Course of Acute Icteric Viral Hepatitis in Type II Diabetes Mellitus Patients and Non-Diabetic Patients:A Pilot Cohort Study Unknown status NCT00689546
28 Case Control Study of Non Viral Hepatitis Relating to Herbal Drug Use in the Emergency Department Unknown status NCT00201578
29 Prediction of Incidence of Liver Cancer or PorTal Hypertension in Patients With Viral Hepatitis by Use of Real-time Tissue Elastography Unknown status NCT01360892
30 Prospective Comparison Between Transient Elastography (TE), Shear Wave Elastography (SWE) and Magnetic Resonance Elastography (MRE) for Non-invasive Assessment of Liver Fibrosis in Patients Affected by Chronic Viral Hepatitis Unknown status NCT03293953
31 Randomized Control Trial of Mesenchymal Stem Cell Transplantation in Decompensated Liver Cirrhosis Resulted From Viral Hepatitis Unknown status NCT03209986
32 Follow-up the Health Condition , Investigation of the Immuno-regulation , and the Study for Interaction of Viral Hepatitis--- Among Patients With or After Dengue Fever Infection Unknown status NCT00688389
33 The Role of Real Time Elastography in the Noninvasive Assessment of Liver Fibrosis in Chronic Viral Hepatitis Unknown status NCT01948687
34 HIV and Hepatitis Care Coordination in Methadone Treatment Completed NCT00608192
35 Impact of Chlordecone Exposure on Evolution of Fibrosis to Cirrhosis in Chronic Hepatitis C, B or Alcoholic, in Guadeloupe. Completed NCT03373396
36 The Role of FGL2-FcgammaRIIB Inhibitory Pathway in Human Viral Hepatitis Completed NCT01711164
37 Time Trend Analysis of the Incidence of Hepatitis- Related Outcomes (Viral Hepatitis A and Unspecified Viral Hepatitis) Reported to the Surveillance System of Panama, 2000-2010 Completed NCT01159951
38 Pre-operative Screening for HIV and Viral Hepatitis B and C: Pilot Study in Stomatology Completed NCT03088995
39 A Randomized Trial of Vaccine Adherence in Young IDU Completed NCT00244374
40 Nurse Case Management to Improve Linkage to Hepatitis C Care and Treatment Initiation in HIV Co-infection: A Randomized Controlled Trial Completed NCT02707991
41 Hepatitis B Virus Prevalence and Risk Factors in Middle Limburg Belgium: the Importance of Migration. Completed NCT03425513
42 Proyecto ESCUDO: Police Training to Reduce Occupational Needlesticks and HIV Among Substance Users Completed NCT02444403
43 Clinical Relevance of Serum Non-organ-specific Antibodies in Hepatitis C Virus Patients Receiving Direct-acting Antiviral Therapy Completed NCT03566966
44 Pilot Educational Intervention to Determine Effect of Intrapartum Testing and Concentrated Postpartum Counseling on Birth Spacing, Breastfeeding, and Infant Vaccination Completion in a Kabul Urban Population. Completed NCT01199601
45 Sero-prevalence of Hepatitis A Varicella-Zoster Virus, Cytomegalovirus, Herpes Simplex and Bordetella Pertussis in Mexico Completed NCT01160081
46 Utility of Shearwave Elastography (SWE) and Non-Invasive Serum Biomarkers to Detect Fibrosis in Pediatric Patients With Liver Diseases Completed NCT01988753
47 Cooperative Agreement to Develop, Implement, and Evaluate Viral Hepatitis and Training Completed NCT00241943
48 Cooperative Agreement to Develop, Implement, and Evaluate Viral Hepatitis and Training Completed NCT00241917
49 Association Between HCV Viral Hepatitis, Blood Sugar Level and Systolic Blood Pressure in the Egyptian Population Completed NCT03839979
50 Evaluation of Innovative Ultrasonic Techniques for Non-invasive Diagnosis of Liver Fibrosis in Patients With Chronic Viral Hepatitis B or C Completed NCT01537965

Search NIH Clinical Center for Viral Hepatitis

Cochrane evidence based reviews: hepatitis, viral, animal

Genetic Tests for Viral Hepatitis

Anatomical Context for Viral Hepatitis

MalaCards organs/tissues related to Viral Hepatitis:

40
Liver, Kidney, Bone, T Cells, Bone Marrow, Thyroid, Heart

Publications for Viral Hepatitis

Articles related to Viral Hepatitis:

(show top 50) (show all 18695)
# Title Authors PMID Year
1
Hepatitis B virus activates deoxynucleotide synthesis in nondividing hepatocytes by targeting the R2 gene. 61 54
20155784 2010
2
Comparison of modes of prothrombin time reporting in patients with advanced liver disease associated with viral hepatitis. 54 61
19330428 2010
3
Systematic review: caspase-cleaved fragments of cytokeratin 18 - the promises and challenges of a biomarker for chronic liver disease. 54 61
19769633 2009
4
Chronic inflammatory demyelinating polyneuropathy after treatment with interferon-alpha. 54 61
19252365 2009
5
Bicyclol: a novel drug for treating chronic viral hepatitis B and C. 54 61
19149648 2009
6
Association of two variants of the interferon-alpha receptor-1 gene with the presentation of hepatitis B virus infection. 54 61
19103527 2008
7
Hepatitis B virus-induced hFGL2 transcription is dependent on c-Ets-2 and MAPK signal pathway. 54 61
18801734 2008
8
Efficacy of triple therapy with thymalfasin, peginterferon alpha-2a, and ribavirin for the treatment of hispanic chronic HCV nonresponders. 54 61
19034238 2008
9
Des-gamma-carboxyprothrombin, alpha-fetoprotein and AFP-L3 in patients with chronic hepatitis, cirrhosis and hepatocellular carcinoma. 54 61
18422961 2008
10
Risk factors for chronic liver disease in Blacks, Mexican Americans, and Whites in the United States: results from NHANES IV, 1999-2004. 61 54
18671818 2008
11
Vitiligo occurring at site of interferon-alpha 2b injection in a patient with chronic viral hepatitis C: a case report. 61 54
18498412 2008
12
Significant correlation between surgical stress of hepatectomy and changes in the serum levels of HGF, IL-6 and soluble Fas in patients with viral hepatitis. 61 54
18795698 2008
13
Natural anticoagulants and fibrinolytic activity following interferon therapy in chronic viral hepatitis. 61 54
18469546 2008
14
Treatment of chronic delta hepatitis with lamivudine vs lamivudine + interferon vs interferon. 61 54
18307594 2008
15
Elevated liver enzymes in Turner syndrome during a 5-year follow-up study. 54 61
18167134 2008
16
The role of interleukin-22 in hepatitis C virus infection. 54 61
18191408 2008
17
Metabolic syndrome is associated with severe fibrosis in chronic viral hepatitis and non-alcoholic steatohepatitis. 54 61
17919273 2008
18
Hyperferritinemia in the Chinese and Asian community: a retrospective review of the University of British Columbia experience. 54 61
18209779 2008
19
HFE C282Y gene variant is a risk factor for the progression to decompensated liver disease in chronic viral hepatitis C subjects in the Czech population. 54 61
17573946 2007
20
Antiplatelet antibodies in patients with chronic viral hepatitis receiving interferon-alpha. 61 54
18019713 2007
21
[A close relationship between viral hepatitis B and Toll-like receptor 2]. 61 54
17669234 2007
22
High aspartate to alanine aminotransferase ratio is an indicator of cirrhosis and poor outcome in patients with primary sclerosing cholangitis. 61 54
17498256 2007
23
Intraocular complications of IFN-alpha and ribavirin therapy in patients with chronic viral hepatitis C. 61 54
17589934 2007
24
Transient elastography: a new surrogate marker of liver fibrosis influenced by major changes of transaminases. 61 54
17439526 2007
25
Modafinil's use in combating interferon-induced fatigue. 61 54
17318387 2007
26
[Two cases of hyperthyroidism induced by interferon-alpha therapy for renal cell carcinoma]. 54 61
17515071 2007
27
Modulation of the IL-12/IFN-gamma axis by IFN-alpha therapy for hepatitis C. 54 61
17148690 2007
28
[Some aspects of human mineral metabolic disturbances in viral hepatitis of various genesis]. 61 54
17436703 2007
29
Autoimmune hepatitis-specific antibodies against soluble liver antigen and liver cytosol type 1 in patients with chronic viral hepatitis. 61 54
17274827 2007
30
[Interferon therapy in chronic viral hepatitis; an autoimmunity dilemma]. 54 61
17941466 2007
31
[Utility of analytical parameters in the diagnosis of liver disease]. 61 54
17373869 2007
32
Rosiglitazone in diabetes control in hemodialysis patients with and without viral hepatitis infection: effectiveness and side effects. 61 54
17192324 2007
33
Cytokeratin 8 and 18 expression in imprint smears of chronic viral hepatitis, autoimmune hepatitis and hepatocellular carcinoma. A preliminary study. 61 54
17328497 2007
34
Efficacy of thymosin alpha-1 and interferon alpha in treatment of chronic viral hepatitis B: a randomized controlled study. 54 61
17075991 2006
35
Molecular detection of transfusion transmitted virus coinfection with some hepatotropic viruses. 54 61
17076531 2006
36
An official ATS statement: hepatotoxicity of antituberculosis therapy. 54 61
17021358 2006
37
Connective tissue growth factor in serum as a new candidate test for assessment of hepatic fibrosis. 61 54
16858074 2006
38
Central hypothyroidism and hypophysitis during treatment of chronic hepatitis C with pegylated interferon alpha and ribavirin. 54 61
16702862 2006
39
Novel mfgl2 antisense plasmid inhibits murine fgl2 expression and ameliorates murine hepatitis virus type 3-induced fulminant hepatitis in BALB/cJ mice. 54 61
16776568 2006
40
Alterations of leptin during IFN-alpha therapy in patients with chronic viral hepatitis. 61 54
16530290 2006
41
Interferon-alpha-induced hyperthyroidism: a three-stage evolution from silent thyroiditis towards Graves' disease. 54 61
16498048 2006
42
Expression of oxidative stress-related molecules in circulating leukocytes and urine in patients with chronic viral hepatitis. 54 61
16448453 2006
43
Incidence and factors predictive of acute renal failure in patients with advanced liver cirrhosis. 54 61
16429839 2006
44
[Progress of the study on the relationship between MxA and interferon therapy of viral hepatitis]. 54 61
16381656 2005
45
A novel panel of blood markers to assess the degree of liver fibrosis. 61 54
16317693 2005
46
Prophylactic alpha interferon treatment increases the therapeutic index of oncolytic vesicular stomatitis virus virotherapy for advanced hepatocellular carcinoma in immune-competent rats. 54 61
16227290 2005
47
Iron in nonhemochromatotic liver disorders. 54 61
16315139 2005
48
[Alanine aminotransferase is a substitute marker of viral hepatitis]. 61 54
16408624 2005
49
Fibrinogen-like protein 2 fibroleukin expression and its correlation with disease progression in murine hepatitis virus type 3-induced fulminant hepatitis and in patients with severe viral hepatitis B. 61 54
16437596 2005
50
Typhoid fever and viral hepatitis in a G6PD deficient individual. 54 61
16599045 2005

Variations for Viral Hepatitis

Expression for Viral Hepatitis

Search GEO for disease gene expression data for Viral Hepatitis.

Pathways for Viral Hepatitis

Pathways related to Viral Hepatitis according to GeneCards Suite gene sharing:

(show all 15)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.79 TNF MX1 IFNA2 IFNA1 FASLG FAS
2
Show member pathways
12.68 TNF IFNA2 IFNA1 FASLG FAS
3 12.67 IFNA2 IFNA1 FASLG FAS F2
4 12.61 TNF IFNA2 IFNA1 FASLG FAS
5
Show member pathways
12.14 TNF MX1 IFNA2 IFNA1 FASLG FAS
6
Show member pathways
12.13 TNF GGT1 F2 ALB
7
Show member pathways
12.03 TNF IFNA2 IFNA1 FASLG FAS
8
Show member pathways
11.93 TNF KRT18 FASLG FAS
9
Show member pathways
11.61 TNF FASLG FAS
10 11.34 TNF FASLG FAS
11 11.25 TNF FASLG FAS
12
Show member pathways
11.25 TNF IFNA2 IFNA1 FASLG FAS
13 11.22 F2 ALB AFP
14 11.07 TNF FASLG FAS
15
Show member pathways
10.99 TNF FASLG FAS

GO Terms for Viral Hepatitis

Cellular components related to Viral Hepatitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 10 TNF SERPINA1 IL18BP IFNA2 IFNA1 FGL2
2 extracellular exosome GO:0070062 9.7 SERPINA1 MIR122 KRT18 IL18BP GPT GGT1
3 external side of plasma membrane GO:0009897 9.63 TNF KRT18 HFE FASLG FAS F2
4 extracellular space GO:0005615 9.5 TNF SERPINA1 MIR122 KRT18 IL18BP IFNA2

Biological processes related to Viral Hepatitis according to GeneCards Suite gene sharing:

(show all 12)
# Name GO ID Score Top Affiliating Genes
1 cellular protein metabolic process GO:0044267 9.8 SERPINA1 F2 ALB AFP
2 blood coagulation GO:0007596 9.73 SERPINA1 IFNA2 IFNA1 F2
3 activation of cysteine-type endopeptidase activity involved in apoptotic process GO:0006919 9.69 TNF FASLG FAS
4 apoptotic signaling pathway GO:0097190 9.65 TNF FASLG FAS
5 type I interferon signaling pathway GO:0060337 9.63 MX1 IFNA2 IFNA1
6 defense response GO:0006952 9.62 TNF MX1 IFNA2 IFNA1
7 humoral immune response GO:0006959 9.58 TNF IFNA2 IFNA1
8 negative regulation of signaling receptor activity GO:2000272 9.54 TNF IL18BP HFE
9 tumor necrosis factor-mediated signaling pathway GO:0033209 9.46 TNF KRT18 FASLG FAS
10 acute-phase response GO:0006953 9.43 SERPINA1 HFE F2
11 extrinsic apoptotic signaling pathway GO:0097191 9.26 TNF KRT18 FASLG FAS
12 necroptotic signaling pathway GO:0097527 8.8 TNF FASLG FAS

Molecular functions related to Viral Hepatitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytokine activity GO:0005125 8.92 TNF IFNA2 IFNA1 FASLG

Sources for Viral Hepatitis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Apr-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....